Direct Healthcare Professional Communication

Xofigo® (radium-223 dichloride): Important safety information update regarding increased incidence of deaths and fractures in a randomized clinical trial with Xofigo used in combination with abiraterone acetate and prednisolone/prednisone

Date: 21 January 2018

Bayer Saudi Arabia LLC.
Al Kamal Import Office
Ittihad St.
P.O Box 15369
21444 Jeddah, Saudi Arabia
Tel: +966126571675
Fax +966126534992
www.bayer.com

Dear Healthcare Professional,
Bayer Saudi LLC in agreement with the National Pharmacovigilance and Drug Safety Centre, Saudi Food and Drug Authority would like to inform you of the following:

Summary

An increased incidence of deaths and fractures has been identified in a randomised clinical trial in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (CRPC) receiving radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone (15396/ERA-223 study).

- The full analysis of the results is not yet completed. Until more information is available, do not treat patients with metastatic castration-resistant prostate cancer with radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone.
- Continued monitoring for fractures should be considered for patients who were previously treated with radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone.
- Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.
- The benefit-risk profile of Xofigo in its approved indication remains positive.

Further information

- The ERA-223 study was a randomised, double-blind, placebo-controlled, multicenter phase III study to investigate the efficacy and safety of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone predominant metastatic castration-resistant prostate cancer.

- Preliminary data showed an increased incidence of fractures (24% vs 7%) and deaths (27% vs 20%) among patients receiving Xofigo in

combination with abiraterone acetate and prednisone/prednisolone (n=401) compared to patients receiving placebo in combination with abiraterone acetate and prednisone/prednisolone (n=405). This study was unblinded early based on an Independent Data Monitoring Committee recommendation however it will continue per protocol.

- The measures outlined above should be followed while there is further investigation of the implications of these findings. Further advice will be communicated as appropriate at the end of the analysis.

The information in this letter has been approved by the Saudi Food and Drug Authority.

Reporting adverse drug reactions

Reporting of adverse drug reactions will allow for quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions to:

National Pharmacovigilance and Drug Safety Centre
Toll free: 8002490000
Fax: +9661 1 2057662
E-Mail: npc.drug@sfda.gov.sa
Online: http://ade.sfda.gov.sa/

Or

Pharmacovigilance department in Bayer Saudi LLC:
Bayer Saudi Arabia LLC.
Al Kamal Import Office
Ittihad St. P.O Box 15369
21444 Jeddah, Saudi Arabia
Tel.: +9661 2 6571675
Fax: +9661 2 6534992
Email: pv.me@bayer.com

If you have any questions, or if you require any further information, please contact the medical information service of
Bayer Saudi LLC
Tel: +9661 2 6571675
Email: med-info.me@bayer.com

With kind regards,

A. Rahman
21 Jan 2018

Abdulrahman Harthi

Pharmacovigilance Specialist, QPPV

Bayer Saudi Arabia LLC.
Al Kamal Import Office
Ittihad St.
P.O Box 15369
21444 Jeddah, Saudi Arab
Tel: +966126571675
Fax +966126534992
www.bayer.com